CT scanners will be able to run clinical applications that are now impractical if they incorporate a line of inexpensive processors set for launch at the RSNA meeting, according to its developer Mercury Computer Systems. The new product line, being built around Mercury's Cell Broadband Engine (CBE) processor, is scheduled to begin shipping in January 2007.
CT scanners will be able to run clinical applications that are now impractical if they incorporate a line of inexpensive processors set for launch at the RSNA meeting, according to its developer Mercury Computer Systems. The new product line, being built around Mercury's Cell Broadband Engine (CBE) processor, is scheduled to begin shipping in January 2007.
"With CBE technology, advanced approaches thought to be too demanding in terms of processing can now enter daily routine," said Marcelo Lima, vice president and general manager, commercial imaging and visualization at Mercury Computer Systems. "Reconstruction algorithms that were previously thought clinically impractical because they took too long, for example, can now be done in orders of magnitude less time."
Company engineers are cooperating with the Institute of Medical Physics in Erlangen, Germany, to implement modern CT reconstruction algorithms delivering real-time performance on CBE-based systems. The cell-based systems might also be used to run advanced processing algorithms in digital radiography devices while keeping complexity and costs of image processing systems within reasonable bounds, according to the company.
Although DR and CT are prime applications, CBE-based systems could also be deployed in PET, ultrasound, and SPECT devices. The processing technology supports cone beam reconstruction algorithms and Monte Carlo-based simulations with close to real-time performance.
"Radiologists will receive better images with higher quality much sooner than ever and critical decisions will be taken more rapidly and more reliably," Lima said.
The systems are designed to provide affordable processing power for high-performance imaging devices. The premiere offering in this line of products will be Mercury's Cell Accelerator Board (CAB), which delivers 180 gigaflops of performance and provides 25 gigabytes of memory bandwidth. CABs, which list for $7999, are designed for use in OEM products along with other PCIe devices, adaptations of the PCI computer bus that allow very fast communications. Several CABs can be implemented simultaneously to boost system performance without changing the footprint of the medical device.
Mercury will market the CBE-based products directly to the developers of imaging equipment. OEMs can work with the basic product. Or they can receive versions optimized with algorithms tailored to fit specific needs of the OEM that Mercury has developed for its CBE technology.
Mercury will also offer two major building blocks that OEMs can use to implement complex algorithms on the CBE-based products. The first is the MultiCore Framework, consisting of a set of software components aimed at implementing, optimizing, and debugging the data distribution between the processing elements of the CBE device. The second, the Scientific Algorithm Library, is a collection of signal and image processing functions optimized for the cell processing elements.
Mercury will make the CAB, as well as its multicore and multicomputer programming expertise, available to all vendors of CT systems, allowing vendors to pick and choose among the company's products and services.
Can MRI-Guided Transurethral Ultrasound Ablation Have an Impact for Localized Prostate Cancer?
December 11th 2023Follow-up MRI imaging one year after transurethral ultrasound ablation revealed approximately 50 percent decreases in prostate volume and median PSA density, according to recently presented research findings at the 2023 Society of Urologic Oncology (SUO) Annual Meeting.
What a New Mammography Study Reveals About BMI, Race, Ethnicity and Advanced Breast Cancer Risk
December 8th 2023In a new study examining population attributable risk proportions (PARPs) based on data from over three million screening mammography exams, researchers found that postmenopausal Black women had the highest BMI-related PARP and premenopausal Asian and Pacific Islander women had the highest breast density-related PARP for advanced breast cancer.
Study: Contrast-Enhanced Mammography Changes Surgical Plan in 22.5 Percent of Breast Cancer Cases
December 7th 2023Contrast-enhanced mammography detected additional lesions in 43 percent of patients and led to additional biopsies in 18.2 percent of patients, over half of whom had malignant lesions, according to a study of over 500 women presented at the recent Radiological Society of North America (RSNA) conference.
What a New Study Reveals About Adjunctive DBT and Early-Stage Invasive Breast Cancer
December 6th 2023The combination of digital breast tomosynthesis (DBT) and digital mammography had a 21.6 higher invasive breast cancer detection rate for stage 1 tumors than digital mammography alone, according to a new study involving nearly 100,000 women.